Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Synthetic Biologics

DB:SFYC
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SFYC
DB
$5M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • Synthetic Biologics has significant price volatility in the past 3 months.
SFYC Share Price and Events
7 Day Returns
-8.1%
DB:SFYC
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-57.3%
DB:SFYC
-13.2%
DE Biotechs
-20.9%
DE Market
SFYC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synthetic Biologics (SFYC) -8.1% -34.9% -50.4% -57.3% -98.6% -99.6%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • SFYC underperformed the Biotechs industry which returned -13.2% over the past year.
  • SFYC underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
SFYC
Industry
5yr Volatility vs Market
Related Companies

SFYC Value

 Is Synthetic Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Synthetic Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Synthetic Biologics. This is due to cash flow or dividend data being unavailable. The share price is €0.2394.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synthetic Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synthetic Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SFYC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.98
AMEX:SYN Share Price ** AMEX (2020-04-03) in USD $0.29
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synthetic Biologics.

DB:SFYC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:SYN Share Price ÷ EPS (both in USD)

= 0.29 ÷ -0.98

-0.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic Biologics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Synthetic Biologics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Synthetic Biologics's expected growth come at a high price?
Raw Data
DB:SFYC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
150%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Synthetic Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Synthetic Biologics's assets?
Raw Data
DB:SFYC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.17
AMEX:SYN Share Price * AMEX (2020-04-03) in USD $0.29
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:SFYC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:SYN Share Price ÷ Book Value per Share (both in USD)

= 0.29 ÷ -0.17

-1.67x

* Primary Listing of Synthetic Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synthetic Biologics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Synthetic Biologics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Synthetic Biologics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Synthetic Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Synthetic Biologics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SFYC Future Performance

 How is Synthetic Biologics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
150%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synthetic Biologics expected to grow at an attractive rate?
  • Synthetic Biologics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Synthetic Biologics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Synthetic Biologics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:SFYC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SFYC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 150%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SFYC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SFYC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31
2021-12-31 0
2020-12-31 0
2020-04-05
DB:SFYC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -14 -16
2019-09-30 -14 -28
2019-06-30 -14 -26
2019-03-31 -15 -27
2018-12-31 -17 -25
2018-09-30 -18 -8
2018-06-30 -19 -22
2018-03-31 -20 -22
2017-12-31 -20 -22
2017-09-30 -27 -27
2017-06-30 -28 -18
2017-03-31 -28 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Synthetic Biologics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Synthetic Biologics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SFYC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Synthetic Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SFYC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-05
DB:SFYC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.98
2019-09-30 -1.78
2019-06-30 -2.12
2019-03-31 -2.91
2018-12-31 -4.06
2018-09-30 -2.01
2018-06-30 -5.90
2018-03-31 -5.96
2017-12-31 -6.23
2017-09-30 -8.09
2017-06-30 -5.73
2017-03-31 -6.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Synthetic Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Synthetic Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synthetic Biologics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SFYC Past Performance

  How has Synthetic Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synthetic Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synthetic Biologics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Synthetic Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Synthetic Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Synthetic Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synthetic Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SFYC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -16.08 4.58 11.08
2019-09-30 -27.85 4.50 11.21
2019-06-30 -26.34 4.88 9.91
2019-03-31 -26.89 5.26 10.89
2018-12-31 -25.29 5.73 11.84
2018-09-30 -7.59 6.75 13.35
2018-06-30 -21.67 6.98 14.64
2018-03-31 -21.67 7.20 15.90
2017-12-31 -22.14 7.67 18.59
2017-09-30 -27.30 8.92 21.76
2017-06-30 -17.83 9.30 24.68
2017-03-31 -19.26 9.81 27.01
2016-12-31 -27.26 10.14 29.11
2016-09-30 -35.86 9.20 31.24
2016-06-30 -34.28 8.71 34.22
2016-03-31 -42.22 8.79 34.57
2015-12-31 -43.74 8.07 32.91
2015-09-30 -39.24 7.40 29.29
2015-06-30 -37.37 7.01 22.94
2015-03-31 -28.30 6.60 18.27
2014-12-31 -19.78 6.01 14.49
2014-09-30 -17.53 4.95 11.96
2014-06-30 -15.99 5.63 9.74
2014-03-31 -13.93 5.07 8.11
2013-12-31 -12.32 5.07 6.51
2013-09-30 -19.99 5.57 14.39
2013-06-30 -18.44 4.75 13.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Synthetic Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Synthetic Biologics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Synthetic Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Synthetic Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synthetic Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SFYC Health

 How is Synthetic Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synthetic Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synthetic Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Synthetic Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synthetic Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Synthetic Biologics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synthetic Biologics Company Filings, last reported 3 months ago.

DB:SFYC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 11.49 0.00 15.05
2019-09-30 14.57 0.00 18.65
2019-06-30 19.59 0.00 21.71
2019-03-31 23.01 0.00 24.69
2018-12-31 26.46 0.00 28.92
2018-09-30 6.55 0.00 9.55
2018-06-30 3.75 0.00 7.13
2018-03-31 7.00 0.00 11.04
2017-12-31 8.64 0.00 17.12
2017-09-30 5.33 0.00 21.05
2017-06-30 2.96 0.00 13.38
2017-03-31 0.76 0.00 13.47
2016-12-31 2.25 0.00 19.06
2016-09-30 -5.98 0.00 4.55
2016-06-30 0.93 0.00 10.05
2016-03-31 4.98 0.00 15.10
2015-12-31 15.00 0.00 20.82
2015-09-30 25.14 0.00 31.81
2015-06-30 -13.66 0.00 4.76
2015-03-31 -1.63 0.00 12.05
2014-12-31 9.56 0.00 17.53
2014-09-30 3.76 0.00 3.29
2014-06-30 8.06 0.00 7.84
2014-03-31 11.76 0.00 11.16
2013-12-31 15.23 0.00 14.63
2013-09-30 6.37 0.00 5.15
2013-06-30 9.40 0.00 6.88
  • Synthetic Biologics has no debt.
  • Synthetic Biologics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Synthetic Biologics has sufficient cash runway for 1.1 years based on current free cash flow.
  • Synthetic Biologics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -0.7% each year.
X
Financial health checks
We assess Synthetic Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synthetic Biologics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SFYC Dividends

 What is Synthetic Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Synthetic Biologics dividends.
If you bought €2,000 of Synthetic Biologics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Synthetic Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Synthetic Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SFYC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SFYC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Synthetic Biologics has not reported any payouts.
  • Unable to verify if Synthetic Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Synthetic Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Synthetic Biologics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Synthetic Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synthetic Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synthetic Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SFYC Management

 What is the CEO of Synthetic Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Shallcross
COMPENSATION $1,108,609
AGE 58
TENURE AS CEO 2.3 years
CEO Bio

Mr. Steven A. Shallcross, also known as Steve, CPA has been Independent Director of Newgioco Group, Inc. since June 13, 2019. Mr. Shallcross has been the Chief Financial Officer, Treasurer and Secretary at Synthetic Biologics, Inc. since joining in June 1, 2015 and also been its Chief Executive Officer since 2018. He had been an Interim Chief Executive Officer at Chief Executive Officer since December 5, 2017. Mr. Shallcross has been a Director of Synthetic Biologics, Inc. since December 6, 2018. He served as the Chief Financial Officer, Executive Vice President, Treasurer and Secretary of Nuo Therapeutics, Inc. (Cytomedix, Inc.) from May 10, 2013 to May 25, 2015. Mr. Shallcross served as the Chief Financial Officer of Innocoll AG (alternative name Innocoll, Inc.) January 2009 to March 2011. He served as Chief Financial Officer, Senior Vice President and Treasurer of Vanda Pharmaceuticals Inc. from November 2005 to January 9, 2009 and also served as its Principal Accounting Officer. He has comprehensive international, financial and operational experience. Significantly, he has extensive expertise in mergers and acquisitions, partnerships and product development collaborations, strategic planning and budgeting, SEC reporting and systems integration and has been instrumental in equity and debt transactions raising over $800 million in capital, including two initial public offerings with various NYSE and NASDAQ listed companies. From October 2001 to November 2005, he served as the Senior Vice President and Chief Financial Officer of MiddleBrook Pharmaceuticals, Inc. (formerly, Advancis Pharmaceutical Corporation). Mr. Shallcross served as Treasurer of MiddleBrook from August 2003 to November 2005, Secretary since October 2001 and also served as its Principal Accounting Officer. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. Mr. Shallcross served as the Vice President of Finance and Chief Financial Officer of Bering Truck Corporation from August 1997 to 2001. From 1993 to 1997, he served as the Vice President of Operations at Precision Scientific, Inc. He served as a Controller of Precision Scientific from June 1993 to January 1994. He serves as the Chairman of the Financial Executive Forum for the Technology Council of Maryland, a board member of the Washington D.C. chapter of Financial Executives International and is a steering committee member for the Baltimore - Washington Area Association of Bioscience Financial Officers. He is a Certified Public Accountant. He was awarded Private Company CFO of the Year by the Tech Councils of Maryland, Northern Virginia and Washington DC. Mr. Shallcross received a Bachelor of Science degree degree in Accounting from the University of Illinois and an M.B.A. from the University of Chicago, Booth School of Business.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team

Steve Shallcross

TITLE
CEO, CFO
COMPENSATION
$1M
AGE
58
TENURE
2.3 yrs

Vincent Perrone

TITLE
Director of Corporate Communication

Vince Wacher

TITLE
Head of Product and Corporate Development

Michael Kaleko

TITLE
Senior Vice President of Research & Development
TENURE
7.5 yrs

Lara Guzman

TITLE
Senior Director of Project Operations
Board of Directors Tenure

Average tenure and age of the Synthetic Biologics board of directors in years:

5.9
Average Tenure
57
Average Age
  • The tenure for the Synthetic Biologics board of directors is about average.
Board of Directors

Jeff Kraws

TITLE
Independent Non-Executive Chairman
COMPENSATION
$242K
AGE
55
TENURE
7.9 yrs

Steve Shallcross

TITLE
CEO, CFO
COMPENSATION
$1M
AGE
58
TENURE
1.3 yrs

Jeff Wolf

TITLE
Independent Director
COMPENSATION
$140K
AGE
56
TENURE
14.3 yrs

Scott Tarriff

TITLE
Independent Director
COMPENSATION
$132K
AGE
59
TENURE
8.2 yrs

Mark Pimentel

TITLE
Chairman of C-IBS Clinical Advisory Board
TENURE
6 yrs

Mark Wilcox

TITLE
Chairman of C Difficile Clinical Advisory Board
TENURE
5.8 yrs

Charles Shoemaker

TITLE
Member of Infectious Disease Scientific Advisory Board
TENURE
7.5 yrs

Curtis Donskey

TITLE
Member of C Difficile Clinical Advisory Board
TENURE
5.8 yrs

Ciarán Kelly

TITLE
Member of C Difficile Clinical Advisory Board
TENURE
5.8 yrs

Tom Louie

TITLE
Member of C Difficile Clinical Advisory Board
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Aug 19 Buy Steven Shallcross Individual 23. Aug 19 23. Aug 19 50,000 €0.37 €18,659
X
Management checks
We assess Synthetic Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synthetic Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SFYC News

Simply Wall St News

SFYC Company Info

Description

Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

Details
Name: Synthetic Biologics, Inc.
SFYC
Exchange: DB
Founded:
$4,547,992
16,806,430
Website: http://www.syntheticbiologics.com
Address: Synthetic Biologics, Inc.
9605 Medical Center Drive,
Suite 270,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX SYN Common Stock NYSE MKT LLC US USD 01. Nov 2006
DB SFYC Common Stock Deutsche Boerse AG DE EUR 01. Nov 2006
Number of employees
Current staff
Staff numbers
11
Synthetic Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 21:18
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/21
Last earnings filing: 2020/02/20
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.